Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

text messaging

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

NFID and CDC urge US adults to get vaccinated against flu and COVID-19

A survey revealed that more than 40% of US adults may not get vaccinated this autumn and winter

- PMLiVE

UKHSA secures UK-based vaccine deal for future influenza pandemics

CSL Sequiris will be ready to produce over 100 million influenza pandemic vaccines

- PMLiVE

CSL Seqirus highlights impact of flu vaccines on reducing strain on healthcare resources

Flu vaccines for older adults in France could reduce hospitalisations by up to 30%

- PMLiVE

NHS bookings for COVID-19 vaccinations open as winter programme starts early

Millions of people in England are now eligible to receive flu and COVID-19 vaccines

- PMLiVE

Moderna shares positive phase 3 results for mRNA influenza vaccine candidate

mRNA-1010 generated a strong immune response against all four WHO-recommended flu strains

- PMLiVE

US CDC recommends updated COVID-19 vaccines for autumn/winter season

Pfizer/BioNTech and Moderna’s updated vaccines will be available in the coming days

- PMLiVE

NHS England to bring forward flu and COVID-19 vaccine programmes

The change follows an announcement on the risks presented by the new BA.2.86 COVID-19 variant

- PMLiVE

FDA authorises first at-home COVID-19 and flu test for emergency use

The single-use test uses nasal swab samples and provides results in about 30 minutes

- PMLiVE

National trial to rapidly find treatments for severe flu this winter launched in UK

REMAP-CAP will test multiple treatments at the same time in thousands of people

Roche Basel Switzerland

Roche’s Tamiflu successor hits the mark in complicated flu

Baloxavir marboxil met its primary objective and cut flu-related complications

- PMLiVE

BioCryst gets FDA nod for first intravenous flu drug

Expects to launch Rapivab in time for this year's flu season

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links